Patterns of hormone therapy use in the Norwegian Women and Cancer study (NOWAC) 1996-2005

Maturitas

Volumn 63, Issue 3, 2009, Pages 220-226

  Waaseth, Marit ^a   Bakken, Kjersti ^a   Lund, Eiliv ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Drug utilization; Hormone therapy; Postmenopausal women; Prevalence of use

Indexed keywords

ESTRADIOL; ESTRIOL; ETHINYLESTRADIOL; GESTAGEN; TIBOLONE;

ADULT; AGE DISTRIBUTION; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG MARKETING; DRUG MEGADOSE; DRUG UTILIZATION; FEMALE; HEALTH CARE POLICY; HORMONAL THERAPY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NORWAY; PREMENOPAUSE; QUESTIONNAIRE; TREATMENT DURATION; UTILIZATION REVIEW;

COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEALTH CARE SURVEYS; HUMANS; MIDDLE AGED; NORPREGNENES; NORWAY; PERIMENOPAUSE; PREMENOPAUSE; QUESTIONNAIRES; TIME FACTORS;

EID: 67649467702     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.03.017     Document Type: Article

References (39)

1. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 (1992) 1016-1037
2. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
3. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
4. Collaborative Group on Hormonal Factors in Breast C. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52. 705 women with breast cancer and 108. 411 women without breast cancer. Lancet 350 (1997) 1047-1059
5. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332 (1995) 1589-1593
6. Schuurman A.G., Brandt P.A., and Goldbohm R.A. Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control 6 (1995) 416-424
7. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362 (2003) 419-427
8. Bakken K., Alsaker E., Eggen A.E., and Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 112 (2004) 130-134
9. Jacobsen S., and Harg P. Hormonsubsitutsjonsbehandling ikke lenger førstevalg ved osteoporose/osteoporoseprofylakse [Hormone substitution is no longer the preferred treatment of osteoporosis/osteoporosis prophylaxis]. Nytt om legemidler 26 7 (2003) 10
10. Jacobsen S., and Harg P. Hormonbehandling av kvinner med menopausale symptomer [Hormonal treatment of women with symptoms of menopause]. Nytt om legemidler 26 (2003) 3-4
11. Guideline on clinical investigation of medicinal products for hormone replacement therapy of estrogen deficiency symptoms in postmenopausal women. Committee for medicinal products for human use (CHMP), The European Agency for the Evaluation of Medicinal Products (EMEA) 2005;EMEA/CHMP/021/97 Rev. 1.
12. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11:11-33.
13. Haas J.S., Kaplan C.P., Gerstenberger E.P., and Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 (2004) 184-188
14. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 (2004) 47-53
15. Faber A., Bouvy M.L., Loskamp L., van de Berg P.B., Egberts T.C.G., and de Jong-van den Berg L.T.W. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the million women study: a follow-up study. Br J Clin Pharmacol 60 (2005) 641-647
16. McIntosh J., and Blalock S.J. Effects of media coverage of women's health initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 62 (2005) 69-74
17. Hallquist A.C., Moen M.H., Andrew M., and Aursnes I. Attitudes to hormone therapy during menopause among Norwegian women [English summary]. Tidsskr Nor Laegeforen 126 (2006) 1195-1197
18. Thunell L., Milsom I., Schmidt J., and Mattsson L.-A. Scientific evidence changes prescribing practice-a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. BJOG: An International Journal of Obstetrics and Gynaecology 113 (2006) 15-20
19. Pedersen A.T., Iversen O.-E., Løkkegaard E., et al. Impact of recent studies on attitudes and use of hormone therapy among Scandinavian gynaecologists. Acta Obstet Gynecol Scand 86 (2007) 1490-1495
20. Bakken K., Eggen A.E., and Lund E. Hormone replacement therapy in Norwegian women, 1996. Maturitas 40 (2001) 131-141
21. In: Rønning M. (Ed). Drug Consumption in Norway 2002-2006 (2007), Norwegian Institute of Public Health, Oslo
22. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114 (2005) 448-454
23. Lund E., Dumeaux V., Braaten T., et al. Cohort profile: the Norwegian women and cancer study-NOWAC-Kvinner og kreft. Int. J. Epidemiol. 37 (2008) 36-41
24. Meland A. Østrogen kan gjøre deg dødssyk [Estrogen can make you lethally ill] (2002), Dagbladet, Oslo
25. Waaseth M., Bakken K., Dumeaux V., et al. Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian women and cancer postgenome cohort-a cross-sectional analysis. BMC Women's Health 8 (2008) 1
26. The Norwegian Prescription Database (NorPD). The Norwegian Institute of Public Health (NIPH); 2008.
27. Carney P.A., Tosteson A.N.A., Titus-Ernstoff L., et al. Hormone therapies in women aged 40 and older: prevalence and correlates of use. Maturitas 53 (2006) 65-76
28. Parazzini F.M.D., et al. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997-2003. Menopause 15 (2008) 164-170
29. de Jong-van den Berg L.T.W., Faber A., and van den Berg P.B. HRT use in 2001 and 2004 in The Netherlands-a world of difference. Maturitas 54 (2006) 193-197
30. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000. BJOG: An International Journal of Obstetrics and Gynaecology 109 (2002) 1319-1330
31. Clanget C., Hinke V., Lange S., Fricke R., Botko R., and Pfeilschifter J. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. changes after HERS II and WHI. Exp Clin Endocrinol Diabetes 113 (2005) 529-533
32. Watson J., Wise L., and Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 63 (2007) 843-849
33. Hery C., Ferlay J., Boniol M., and Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 19 (2008) 1009-1018
34. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
35. Katalinic A., and Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107 (2008) 427-430
36. Verkooijen H., Koot V., Fioretta G., et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 107 (2008) 389-395
37. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 57 (2007) 81-84
38. Parente L., Uyehara C., Larsen W., Whitcomb B., and Farley J. Long-term impact of the women's health initiative on HRT. Arch Gynecol Obstet 277 (2008) 219-224
39. Lund E., Kumle M., Braaten T., et al. External validity in a population-based national prospective study-the Norwegian women and cancer study (NOWAC). Cancer Causes Control 14 (2003) 1001-1008